Tell us a little bit about, what got you interested in metabolic health to begin with, and maybe how that led you to think about GLP-1s and so forth
Despite a reduction in potency relative to these standards, the observed GIPR activity suggests its potential as a molecular starting point for the rational design of triple-acting ligands (GLP-1R/GIPR/DOR)
Nevertheless, if the infection is prevalent, it is reasonable to hypothesize that the response triggered by Nrf2 signalling is too weak or delayed [139]
The refined TED outcome, which focuses on pathognomonic manifestations, followed the same trend, showing a protective effect at all time points, including a one-year risk of 0.42% in the GLP-1 group compared to 0.53% in the control group (HR 0.79)
Its currently before the FDAs Pharmacy Compounding Advisory Committee for potential inclusion on the 503A Bulks List, which is a separate process from drug approval but shows regulators are actively engaging with it
Compounded semaglutide from $199/mo